Breaking News Instant updates and real-time market news.

ALPN

Alpine Immune Sciences

$2.89

-0.03 (-1.03%)

, CUE

Cue Biopharma

$8.90

0.39 (4.58%)

04:55
11/10/19
11/10
04:55
11/10/19
04:55

Society for Immunotherapy of Cancer to hold annual meeting

34th Annual Meeting of SITC will be held in National Harbor, Maryland on November 6-10.

ALPN

Alpine Immune Sciences

$2.89

-0.03 (-1.03%)

CUE

Cue Biopharma

$8.90

0.39 (4.58%)

HTBX

Heat Biologics

$0.49

-0.0082 (-1.64%)

AGEN

Agenus

$3.57

-0.12 (-3.25%)

ALKS

Alkermes

$20.10

0.38 (1.93%)

CRVS

Corvus Pharmaceuticals

$3.44

-0.35 (-9.23%)

IOVA

Iovance Biotherapeutics

$23.63

2.97 (14.38%)

THOR

Synthorx

$15.99

1.86 (13.16%)

SURF

Surface Oncology

$1.74

0.02 (1.16%)

TMO

Thermo Fisher

$294.51

1.09 (0.37%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$45.84

0.385 (0.85%)

REGN

Regeneron

$341.94

15.88 (4.87%)

PFE

Pfizer

$37.04

0.12 (0.33%)

ILMN

Illumina

$293.23

-2.08 (-0.70%)

INCY

Incyte

$84.98

2.23 (2.69%)

AZN

AstraZeneca

$47.25

0.46 (0.98%)

BMY

Bristol-Myers

$58.00

0.41 (0.71%)

GILD

Gilead

$65.34

1.36 (2.13%)

NWBO

Northwest Biotherapeutics

$0.00

(0.00%)

NVS

Novartis

$88.40

1.34 (1.54%)

NEO

NeoGenomics

$22.69

0.68 (3.09%)

MYGN

Myriad Genetics

$23.64

0.12 (0.51%)

MRK

Merck

$83.59

0.68 (0.82%)

FPRX

Five Prime

$3.90

0.01 (0.26%)

  • 10

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 22

    Nov

  • 02

    Dec

  • 05

    Dec

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

ALPN Alpine Immune Sciences
$2.89

-0.03 (-1.03%)

05/15/19
PIPR
05/15/19
NO CHANGE
Target $11
PIPR
Overweight
Piper sees broad partnership potential for Alpine after Adaptimmune deal
After Alpine Immune Sciences (ALPN) announced a partnership with Adaptimmune (ADAP) to incorporate its novel Transmembrane and Secreted Immunomodulatory Proteins, or TIPs and SIPs, into CAR-T cells, Piper Jaffray analyst Edward Tenthoff said he sees Alpine having broad potential to partner its TIPs and SIPs for next generation cellular therapies. The analyst, who noted that Alpine is also advancing a platform of novel variant Ig domains, or "vIgDs," to augment T-cell activation, keeps an Overweight rating and $11 price target on Alpine shares.
05/24/19
PIPR
05/24/19
NO CHANGE
Target $11
PIPR
Overweight
Alpine Immune Sciences Kite pact termination 'a win,' says Piper Jaffray
Last week's new collaboration and license agreement between Alpine Immune Sciences (ALPN) with Adaptimmune (ADAP) essentially replaced the old deal between Kite Pharma and Gilead (GILD), termination of which was announced in a regulatory filing earlier today and is driving Alpine shares lower, Piper Jaffray analyst Edward Tenthoff tells investors in a research note to investors. Tenthoff says he sees this as a win for Alpine, who received $2M upfront and is eligible for an additional $288M in milestones, adding that he is a buyer of Alpine Immune Sciences on today's weakness ahead of ALPN-101 safety and biomarker data this quarter. Tenthoff maintains an Overweight rating and $11 price target on Alpine Immune Sciences shares.
01/22/19
PIPR
01/22/19
NO CHANGE
Target $11
PIPR
Overweight
Alpine Immune Sciences target lowered to $11 placement dilution at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Alpine Immune Sciences to $11 from $12 to reflect dilition from the company's recent private placement. Alpine recently issued 4.7 million units at $5.37 comprised of one share and 0.39 warrants with a $12.74 strike price raising gross proceeds of $25.3M, Tenthoff tells investors in a research note. The analyst estimates Alpine now holds pro forma cash of $86M to advance its pipeline of proprietary variant Ig domains as novel immunotherapies. He reiterates an Overweight rating on the shares.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
CUE Cue Biopharma
$8.90

0.39 (4.58%)

07/26/19
07/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dentsply Sirona (XRAY) initiated with an In Line at Evercore ISI. 2. BridgeBio (BBIO) initiated with an Outperform at Raymond James. 3. Crispr Therapeutics (CRSP) initiated with a Buy at Canaccord. 4. GeoPark (GPRK) initiated with a Buy at GMP Securities. 5. Neon Therapeutics (NTGN), Gritstone Oncology (GRTS), and Cue Biopharma (CUE) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/19
BARD
07/25/19
INITIATION
Target $13
BARD
Outperform
Cue Biopharma initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Cue Biopharma with an Outperform and $13 price target.
HTBX Heat Biologics
$0.49

-0.0082 (-1.64%)

07/29/19
BRKL
07/29/19
INITIATION
Target $8
BRKL
Buy
Heat Biologics initiated with a Buy at Brookline
Brookline Capital Markets analyst Kumaraguru Raja initiated Heat Biologics with a Buy and $8 price target.
AGEN Agenus
$3.57

-0.12 (-3.25%)

04/22/19
04/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Sell at Summit Insights. 2. Agenus (AGEN) initiated with a Buy at B. Riley FBR. 3. Aquestive Therapeutics (AQST) initiated with a Buy at H.C. Wainwright. 4. Akamai (AKAM) initiated with a Buy at Needham. 5. Six Flags (SIX) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/22/19
RILY
04/22/19
INITIATION
Target $5
RILY
Buy
B. Riley FBR starts Agenus with Buy rating, $5 price target
B. Riley FBR analyst Harshita Polishetty initiated coverage of Agenus with a Buy rating and $5 price target. The company's in-house capabilities allow for multiple large pharma collaborations, Polishetty tells investors in a research note. Further, the analyst believes Agenus' wholly owned anti-PD-1 and anti-CTLA-4 candidates will allow for competitive pricing when both products ultimately reach the market. It is also developing potential off-the-shelf cancer vaccines and adoptive cell therapies, which can be used in combination with the company's antibody platform to find the optimal combination for different cancers, Polishetty says.
04/22/19
RILY
04/22/19
INITIATION
Target $5
RILY
Buy
Agenus initiated with a Buy at B. Riley FBR
B.Riley FBR analyst Harshita Polishetty started Agenus with a Buy rating and $5 price target.
ALKS Alkermes
$20.10

0.38 (1.93%)

10/23/19
PIPR
10/23/19
NO CHANGE
Target $22
PIPR
Neutral
Alkermes making some positive changes, says Piper Jaffray
Piper Jaffray analyst Danielle Brill said she believes Alkermes "is making some positive changes" with its restructuring plans, adding that the company's need for pipeline growth was reinforced by "another disappointing revision" to its outlook for Aristada revenue. In Q3, Aristada's slower than anticipated growth was offset by higher than anticipated Sustenna royalties, helping the company to beat revenue expectations and maintain its FY19 guidance, Brill noted. She doubts that the company's Vumerity and 3831 opportunities will offset upcoming royalty expirations, leading her to keep a Neutral rating on the stock, but Brill added that she could get more constructive on Alkermes if it makes promising pipeline additions.
11/01/19
HCWC
11/01/19
NO CHANGE
Target $26
HCWC
Neutral
Alkermes price target lowered to $26 from $28 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao lowered his price target for Alkermes (ALKS) to $26 from $28 and reiterates a Neutral rating on the shares. With announced rationalization of the cost structure and launch of Vumerity as well as expected launch of ALKS-3831, the analyst expects the company to achieve non-GAAP profitability. He thinks Vumerity could eventually represent 25%-30% of the Tecfidera/Vumerity franchise, although he would like to see how aggressively Biogen (BIIB) promotes Vumerity before ascribing that much value. However, Tsao is doubtful that earnings based on the launches of Vumerity and ALKS-3831 can command an earnings multiple "that can take shares meaningfully" higher. Sentiment around ALKS-4230 could be the key driver of Alkermes shares over the next two years, the analyst adds.
10/23/19
STFL
10/23/19
NO CHANGE
Target $23
STFL
Hold
Alkermes price target lowered to $23 from $25 at Stifel
Stifel analyst Paul Matteis lowered his price target for Alkermes to $23 from $25 and reiterates a Hold rating on the shares. The Q3 results were a "mixed bag," as the misses for Aristada and Vivitrol were balanced by the restructuring announcement, Matteis tells investors in a post-earnings research note. Investors will be happy to see some cost discipline from Alkermes, as the company's margin expansion story "hasn't played out as well as some investors had hoped," adds the analyst. Matteis reduced some of his long-term Vivitrol and Aristada projections.
09/05/19
MSCO
09/05/19
UPGRADE
Target $20
MSCO
Equal Weight
Alkermes upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst David Risinger upgraded Alkermes to Equal Weight from Underweight while lowering his price target for the shares to $20 from $30. The stock has underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent, Risinger tells investors in a research note. Although cancer pipeline candidate ALKS 4230 could still disappoint, consensus expectations are low due to a questionable profile, adds the analyst. He believes Alkermes' long-term risk to royalty streams is balanced by its pipeline or cost savings optionality at current share levels.
CRVS Corvus Pharmaceuticals
$3.44

-0.35 (-9.23%)

05/28/19
ROTH
05/28/19
INITIATION
Target $6
ROTH
Buy
Corvus Pharmaceuticals initiated with a Buy at Roth Capital
Roth Capital initiated Corvus Pharmaceuticals initiated with a Buy and $6 price target.
09/11/19
MZHO
09/11/19
INITIATION
Target $7
MZHO
Buy
Corvus Pharmaceuticals initiated with a Buy at Mizuho
Mizuho started orvus Pharmaceuticals with a Buy rating and $7 price target.
05/28/19
ROTH
05/28/19
INITIATION
Target $6
ROTH
Buy
Roth Capital starts Corvus with Buy rating, $6 price target
Roth Capital analyst Tony Butler initiated coverage of Corvus Pharmaceuticals with a Buy rating and $6 price target. The analyst projects peak risk-adjusted revenues of $482M in non-small-cell lung carcinoma and renal cell carcinoma from Corvus' lead program ciforadenant. Further, expected clinical updates from the CPI-006 and CPI-818 programs during 2019 could result in "significant upside" to estimates, Butler tells investors in a research note. He believes the company has an expanding pipeline with the potential for exploring novel combinations, which he says is where the "clinical paradigm is heading."
09/12/19
MZHO
09/12/19
INITIATION
Target $7
MZHO
Buy
Mizuho starts Corvus Pharmaceuticals with Buy rating, $7 price target
Mizuho analyst Mara Goldstein last night initiated coverage of Corvus Pharmaceuticals with a Buy rating and $7 price target. The analyst likes the adenosine-A2AR pathway and believes there is promise in combination therapy. While the shares have struggled due to "underwhelming" ciforadenant monotherapy data, CPI-006 offers an opportunity to reset expectations, Goldstein tells investors in a research note.
IOVA Iovance Biotherapeutics
$23.63

2.97 (14.38%)

09/30/19
STFL
09/30/19
INITIATION
Target $27
STFL
Buy
Iovance Biotherapeutics initiated with a Buy at Stifel
Stifel analyst Benjamin Burnett started Iovance Biotherapeutics with a Buy rating and $27 price target. The analyst says his physician checks corroborate the view that the company's lifileucel and LN-145 data are "very good" and supportive of being the best therapeutic option in their respective advanced settings. He believes the market opportunity for an autologous tumor-infiltrating lymphocyte product in the advanced melanoma/cervical cancer setting can reach $2B-plus sales at peak.
08/26/19
JEFF
08/26/19
NO CHANGE
Target $33
JEFF
Buy
Iovance pullback brings buying opportunity, says Jefferies
Jefferies analyst Biren Amin views the recent pullback in shares of Iovance Biotherapeutics as a buying opportunity into the end of 2019. After meeting with management, the analyst believes the melanoma and cervical pivotal cohorts appear to be enrolling patients with Iovance on track toward finishing patient enrollment in the melanoma study in Q1 of 2020. He thinks there is some likelihood of data at SITC in November and keeps a Buy rating on the shares with a $33 price target.
11/08/19
PIPR
11/08/19
NO CHANGE
Target $30
PIPR
Overweight
Iovance data suggests durable responses in melanoma study, says Piper Jaffray
After Iovance Biotherapeutics presented new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study, Piper Jaffray analyst Joseph Catanzaro said the fact that median duration of response, or DOR, has not yet been reached at a median follow-up of 12.8 months per investigator assessment suggests durable responses are being seen with the drug. The analyst, who said he expects the data to continue to "mature favorably," sees ultimate implications on commercial adoption and peak penetration, he noted. He keeps an Overweight rating on Iovance shares.
07/02/19
HCWC
07/02/19
NO CHANGE
Target $32
HCWC
Buy
H.C. Wainwright reiterates Buy, $32 price target on Iovance
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics with a $32 price target after the company disclosed updates regarding the regulatory path for LN-145 in cervical cancer. With the possibility for innovaTIL-04 study to be registrational, the company is "reasonably" planning a path for a Biologics License Application submission in the second half of 2020, Pantginis tells investors in a research note. The analyst believes LN-145 "deserves the attention it is receiving." While the primary focus remains on Iovance's initial path to market with lifileucel in melanoma, LN-145 is a "potential rapid follower to commercialization," says Pantginis.
THOR Synthorx
$15.99

1.86 (13.16%)

01/02/19
HCWC
01/02/19
INITIATION
Target $30
HCWC
Buy
Synthorx initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Synthorx with a Buy rating and $30 price target. The company's Expanded Genetic Alphabet technology gives it the ability to manipulate the innate biological interaction of cytokines and adapt them to applications either in oncology or autoimmune diseases, "expanding the versatility and scope of the platform," says the analyst.
01/02/19
JEFF
01/02/19
INITIATION
Target $21
JEFF
Buy
Jefferies starts Synthorx with Buy rating, $21 price target
Jefferies analyst Biren Amin initiated coverage of Synthorx (THOR) with a Buy rating and $21 price target. Based on preclinical data, the analyst believes THOR-707 could have differentiated properties compared to other IL-2 therapies and may drive monotherapy efficacy. He thinks THOR-707 will have a fast follower clinical development strategy to Nektar's (NKTR) NKTR-214. Further, Amin believes Synthorx's early pipeline offers additional upside.
01/02/19
01/02/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Concho Resources (CXO) initiated with an Overweight at KeyBanc. 2. Synthorx (THOR) initiated with a Buy at Jefferies and H.C. Wainwright. 3. Concrete Pumping (BBCP) initiated with a Buy at B. Riley FBR. 4. Moderna (MRNA) was initiated with an Outperform at Oppenheimer, an Overweight at Morgan Stanley, Barclays, JPMorgan, and Piper Jaffray, as well as a Buy at Needham, BofA/Merrill, and Goldman Sachs. 5. GW Pharmaceuticals (GWPH) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/15/19
LEER
03/15/19
INITIATION
Target $27
LEER
Outperform
Synthorx initiated with an Outperform at SVB Leerink
SVB Leerink initiated Synthorx with an Outperform and $27 price target.
SURF Surface Oncology
$1.74

0.02 (1.16%)

06/27/19
JONE
06/27/19
INITIATION
Target $12
JONE
Buy
Surface Oncology initiated with a Buy at JonesTrading
JonesTrading analyst Soumit Roy started Surface Oncology with a Buy rating and $12 price target. The company's "differentiated approach" involves targeting the first enzyme in the enzymatic pathway, CD39, and a novel target, IL-27, to block overexpression of CD39 and T cell inhibiting receptors, Roy tells investors in a research note. He believes the stock at current levels is "squarely in the oversold territory."
TMO Thermo Fisher
$294.51

1.09 (0.37%)

10/08/19
CLVD
10/08/19
NO CHANGE
CLVD
Cleveland sees 'noticeable' slowdown in Life Science equipment demand
Cleveland Research analyst Steve Willoughby says his recent research suggests a "noticeable slowing" in Life Science equipment demand during Q3 in Europe, China, and parts of the U.S. The analyst who adjusted estimates for Thermo Fisher (TMO), Waters (WAT), Agilent (A), Mettler-Toledo (MTD), Avantor (AVTR), PerkinElmer (PKI) and Bruker (BRKR), believes a broader industry slowdown could impact industry multiples which he notes have expanded so far this year.
10/24/19
BARD
10/24/19
NO CHANGE
Target $319
BARD
Outperform
Thermo Fisher price target raised to $319 from $305 at Baird
Baird analyst Catherine Ramsey Schulte raised her price target on Thermo Fisher to $319 from $305 following strong Q3 results. The analyst sees room for upside to 2019 guidance and notes she wouldn't be surprised to see incremental capital deployment in the next 6-12 months given it deleveraging progress. Ramsey Schulte reiterated her Outperform rating on Thermo Fisher shares.
10/23/19
JPMS
10/23/19
NO CHANGE
Target $330
JPMS
Overweight
Thermo Fisher price target raised to $330 from $315 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Thermo Fisher to $330 from $315 and maintained an Overweight rating following the company's "robust" Q3 results. In a research note to investors, Peterson says Thermo Fisher delivered a robust quarter overall against an unprecedented tough comp, and along with its resilience to macro risks, a long runway for margin expansion and capital deployment optionality, says he continues to like the set-up.
10/16/19
CLVD
10/16/19
NO CHANGE
CLVD
Neutral
Thermo Fisher growth rate has moderated from first half, says Cleveland Research
Cleveland Research analyst Steve Willoughby said his recent checks suggest Thermo Fisher's growth rate has likely moderated from the first half of the year due to slower trends in Europe and China that are likely being somewhat offset by continued U.S. strength. He sees Q3 as "likely in-line" and thinks FY19 guidance appears realistic, though he said he is more concerned that the "end of year budget flush may be less impactful as compared to the past two years," Willoughby tells investors. He keeps a Neutral rating on Thermo Fisher shares.
RHHBY Roche
$0.00

(0.00%)

10/15/19
BOFA
10/15/19
NO CHANGE
BOFA
Europe 1 List changes at BofA/Merrill
BofA/Merrill added Roche (RHHBY) and Sanofi (SNY) to the Europe 1 List and removed AstraZeneca.
10/15/19
CANT
10/15/19
NO CHANGE
Target $65
CANT
Neutral
Cantor keeps Neutral on Ionis after Roche boosts Phase 3 study size
Roche (RHHBY) disclosed yesterday that the size of the RG6042 Phase 3 trial in Huntington's increased from 660 people to 801, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. Per company comments, this is driven by high patient demand and potential to increase statistical power, particularly for the Q16W dose, adds the analyst. Merle, however, thinks investors might see this change as suggesting the Phase 3 needed more patients for sufficient powering. For her part, the analyst continues to see Huntington's as a challenging indication to study in a clinical trial setting. The higher patient number should improve the likelihood of statistical success, however, says Merle. The analyst, who believes Huntington's is the key stock focus for Ionis Pharmaceuticals investors, keeps a Neutral rating on Ionis shares with a $65 price target.
11/01/19
HCWC
11/01/19
NO CHANGE
Target $22
HCWC
Buy
Dicerna HBV deal earlier, on better terms than expected, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirmed his Buy rating on Dicerna Pharmaceuticals (DRNA) shares after the companpy announced a collaboration and licensing agreement with Roche (RHHBY) for the worldwide development and commercialization the company's lead asset for the treatment of hepatitis B virus, or HBV. While he has long anticipated "a large HBV deal," the collaboration with Roche is earlier, and with better economics, than Arce had expected, the analyst tells investors. He maintains a $22 price target on Dicerna shares.
11/01/19
LEER
11/01/19
NO CHANGE
Target $26
LEER
Outperform
Dicerna price target raised to $26 from $22 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna Pharmaceuticals (DRNA) to $26 from $22 saying the terms for the company's partnership with Roche (RHHBY) to develop and commercialize DCR-HBVS are "quite favorable." Dicerna will receive a $200M upfront payment, up to $1.47B in potential milestones, and up to mid-teens royalties on future sales. The transaction is "meaningfully validating" for Dicerna's strategy for large population indications, Foroohar tells investors in a research note. With shares trading at an implied enterprise value "materially below" the pre-deal value, investors should begin to appreciate the scope of the potential partnership opportunities, says the analyst. He keeps an Outperform rating on Dicerna.
SNY Sanofi
$45.84

0.385 (0.85%)

09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
10/02/19
STFL
10/02/19
NO CHANGE
Target $45
STFL
Buy
Stifel remains buyer of Principia Biopharma into Q4 data readouts
Stifel analyst Derek Archila remains bullish and a buyer of Principia Biopharma (PRNB) shares ahead of the company's two Phase 2 readouts for PRN1008 in immune thrombocytopenia and pemphigus vulgaris. The shares could reach the mid-$50 range if results are positive, Archila tells investors in a research note. He believes the bogey for each study is not that high and keeps a Buy rating on Principia with a $45 price target. The two clinical catalysts, coupled with Phase 2 data expected in the first half of 2020 from the company's partnered program with Sanofi (SNY) in multiple sclerosis, offers "multiple shots for valuation creation" over the next nine months.
REGN Regeneron
$341.94

15.88 (4.87%)

11/07/19
11/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Regeneron (REGN) upgraded to Buy from Neutral at Citi with analyst Mohit Bansal saying the Libtayo data in 2020 and continuous Dupixent growth will make it easy to keep owning Regeneron shares through near-term Eylea competition. 2. Match Group (MTCH) upgraded to Buy from Neutral at UBS with analyst Eric Sheridan saying Match shares experience a post-earnings selloff yesterday after already being notably down since August on the back of the Facebook (FB) Dating launch and legal proceedings. 3. Sealed Air (SEE) upgraded to Sector Weight from Underweight at KeyBanc with analyst Adam Josephson saying shares have underperformed the S&P 500 by 1,400 bps since its downgrade on July 14. 4. Elanco (ELAN) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying the current valuation on the stock discounts investor concerns regarding the impact on its swine products from African Swine Fever and competitive threats, noting that his rating change reflects an opportunity on the stock following the recent pullback in price. 5. DexCom (DXCM) upgraded to Buy from Neutral at Guggenheim. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/19
SBSH
11/06/19
UPGRADE
Target $420
SBSH
Buy
Regeneron upgraded to Buy from Neutral at Citi
Citi analyst Mohit Bansal upgraded Regeneron to Buy from Neutral with a price target of $420, up from $340.
11/06/19
SBSH
11/06/19
UPGRADE
Target $420
SBSH
Buy
Citi upgrades Regeneron to Buy, boosts target to $420 from $340
Citi analyst Mohit Bansal upgraded Regeneron Pharmaceuticals to Buy from Neutral with a price target of $420, up from $340. The Libtayo data in 2020 and continuous Dupixent growth will make it easy to keep owning Regeneron shares through near-term Eylea competition, Bansal tells investors in a research note. The analyst remains bullish on Dupixent and sees $10B in peak sales versus the current run rate of $2.5B. With Libtayo's profile "looking very similar to Keytruda," the analyst feels "incrementally confident" and likes Regeneron's risk/reward profile.
11/06/19
OPCO
11/06/19
NO CHANGE
Target $430
OPCO
Outperform
Regeneron price target lowered to $430 from $480 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Regeneron to $430 from $480 after the company reported quarterly earnings and provided an investor update. In a research note to investors, Singh says Regeneron's Q3 update validated the potential best-in-class pipeline in ophthalmology, immunology, and oncology, coupled with commercial execution that is being powered by Eylea and Dupixent, but says non-GAAP OPEX still grew at a faster rate than sales quarter-over-quarter, leading to a 100bps reduction in the non-GAAP operating margin, the one area Regeneron trails its peer group. He stays bullish and keeps an Outperform rating on the shares.
PFE Pfizer
$37.04

0.12 (0.33%)

11/06/19
PIPR
11/06/19
NO CHANGE
Target $70
PIPR
Neutral
Ionis Pharmaceuticals price target lowered to $70 from $75 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target on Ionis Pharmaceuticals (IONS) to $70 and kept his Neutral rating after its Q3 results, saying that while the quarter was "strong" thanks to the recent $250M upfront payment from Pfizer (PFE), results for its Tegsedi were "uninspiring". The analyst states that an acceleration in Tegsedi is needed soon for him to become more positive on the name ahead of the "potential Phase I/II OLE +natural history Huntington's study readouts next year."
10/17/19
BOFA
10/17/19
INITIATION
Target $37
BOFA
Neutral
Pfizer reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Pfizer with a Neutral rating and $37 price target. The analyst believes valuation reflects the near-term pipeline and the need for visibility on the pipeline to offset future LOEs.
10/22/19
WEDB
10/22/19
NO CHANGE
Target $186
WEDB
Outperform
Ascendis Pharma price target lowered to $186 from $191 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Ascendis Pharma (ASND) to $186 from $191 after competitors Opko Health (OPK) and Pfizer (PFE) announced topline results from a global Phase 3 trial evaluating somatrogon in pre-pubertal children with growth hormone deficiency. Given, Pfizer's role in registering and commercializing somatrogon, the analyst can see a potentially similar regulatory timeline to Ascendis, noting that the latter anticipates BLA and MAA submissions in the first half and second half of 2020, respectively. Nonetheless, Moussatos reiterates an Outperform rating on Ascendis shares as she remains positive on TC-hGH despite competition.
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
ILMN Illumina
$293.23

-2.08 (-0.70%)

10/25/19
GUGG
10/25/19
INITIATION
Target $350
GUGG
Buy
Illumina initiated with a Buy at Guggenheim
Guggenheim analyst David Westenberg initiated coverage of Illumina with a Buy rating and $350 price target.
10/25/19
GUGG
10/25/19
INITIATION
Target $350
GUGG
Buy
Guggenheim says Illumina 'best way to invest in genomic medicine,' starts at Buy
As previously reported, Guggenheim analyst David Westenberg initiated coverage of Illumina with a Buy rating and $350 price target, calling the stock the "best way to invest in genomic medicine." He thinks bear arguments around instrument cycles or PopSEQ funding delays have created an attractive entry point into the stock and recommends investors focus on emerging clinical sequencing opportunities where growth appears to be accelerating. Illumina has limited competitors in its fastest growing business areas and he sees it remaining one of the key technologies in the genomic medicine of the next decade, Westenburg added.
10/15/19
PIPR
10/15/19
UPGRADE
Target $8
PIPR
Overweight
Pacific Biosciences upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Pacific Biosciences of California (PACB) to Overweight from Neutral with an unchanged price target of $8. The analyst's Sequel II checks imply 36 to 42 placements in Q3, above his original 35 estimate. The market has been preoccupied with concerns about the Illumina (ILMN) deal falling through, and Pacific's valuation does not reflect the Sequel II launch, Quirk tells investors in a research note. If the deal fails, he believes Pacific Biosciences should be valued at seven times estimated 2020 revenue, or just under $8 per share. The stock closed Monday at $5.13. The analyst cites "strong" channel checks and the current valuation for his upgrade to Overweight.
10/07/19
PIPR
10/07/19
NO CHANGE
Target $348
PIPR
Overweight
Illumina checks show 70 NovaSeq placements this quarter, says Piper Jaffray
Piper Jaffray analyst William Quirk says his channel checks suggested Illumina had ~70 NovaSeq placements this quarter, in line with his estimate. He believes institutions like DeCode Genetics and Sanger are ramping their instrument fleets ahead of large upcoming PopGen projects like UK BioBank. The analyst, who says his checks typically find about 50% of NovaSeq placements each quarter, keeps an Overweight rating on Illumina shares with a $348 price target.
INCY Incyte
$84.98

2.23 (2.69%)

10/16/19
STFL
10/16/19
NO CHANGE
STFL
Hold
Incyte REACH2 wins on ORR, secondary endpoint data just as important,says Stifel
Stifel analyst Stephen Willey believes Incyte's disclosure of top-line Phase 3 REACH2 results demonstrating ruxolitinib yields a statistically significant improvement in Day 28 overall response rate versus best available therapy in patients with steroid-refractory, acute graft-versushost-disease - the trial's primary efficacy endpoint - is in-line with most investor expectations. The analyst believes the yet-to-be-disclosed secondary efficacy endpoints will be of particular interest to both investors/clinicians. He also argues that the Phase 3 REACH3 trial evaluating ruxolitinib versus BAT in steroid-refractory chronic GVHD represents the more meaningful trial for his longer-term ruxolitinib estimates, but also likely carries the greatest risk. He has a Hold rating on Incyte's shares.
10/24/19
JMPS
10/24/19
NO CHANGE
JMPS
JMP reiterates Outperform on Incyte following Phase 2 results for rux cream
JMP Securities analyst Reni Benjamin reiterated an Outperform rating and $110 price target on Incyte Corporation, with the analyst citing a discounted EPS and revenue multiple analysis and the potential of the company's rux cream for vitiligo, following its positive 52-week Phase 2 results from last week.
10/29/19
PIPR
10/29/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte on pace to easily achieve long-term Jakafi guidance, says Piper Jaffray
Incyte reported "strong" Q3 results as the Jakafi franchise continues its solid growth, Piper Jaffray analyst Tyler Van Buren tells investors in a post-earnings research note. The analyst say he's encouraged to hear that the initial Jakafi launch in refractory acute graft versus host disease has been outpacing internal expectations. These updates suggest that the $2.5B-$3.0B long-term Jakafi guidance by 2027 "will be easily achieved," Van Buren says. He sees long-term upside from current share levels and reiterates an Overweight rating on Incyte with a $95 price target.
10/16/19
PIPR
10/16/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte REACH2 'a nice win,' data should be presented at ASH, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren notes that Incyte announced that REACH2, which is evaluating Jakafi in steroid-refractory acute GvHD, "nicely" met its primary response rate-based endpoint and he believes the data could be presented at ASH. Further, the company disclosed that the REACH3 trial is continuing as planned after an interim efficacy and safety review by the data monitoring committee, although the analyst estimates the data is now delayed until Q3 of 2020. Therefore, by year-end, the remaining major GvHD catalyst is the GRAVITAS-301 trial, which will likely come in December, Van Buren points out, adding that he believes should be a success. While the delay is "slightly frustrating," the analyst still finds the broader REACH2+3 update to be "encouraging" for the overall GvHD franchise, which could generate $500M-plus in sales by 2025. He has an Overweight rating and $95 price target.
AZN AstraZeneca
$47.25

0.46 (0.98%)

11/05/19
JEFF
11/05/19
NO CHANGE
Target $75
JEFF
Buy
Jefferies sees nothing new in FibroGen short report
Jefferies analyst Michael Yee does not see "anything really new" in yesterday's short report on FibroGen. The report is all based on earlier small Phase II/III studies that are already known, as well as on studies in China/Japan, where the drug has recently been approved, Yee tells investors in a research note. Moreover, FibroGen partner AstraZeneca (AZN) has publicly stated it is comfortable with the data, adds Yee. He keeps a Buy rating on FibroGen shares with a $75 price target
10/28/19
GUGG
10/28/19
INITIATION
Target $44
GUGG
Buy
Guggenheim starts Viela Bio at Buy, makes stock Best Idea
Guggenheim analyst Seamus Fernandez initiated coverage of Viela Bio with a Buy rating and $44 price target. The analyst makes the stock his Best Idea, seeing a potential path to a three-to-five times return over the next five years. Viela is a "uniquely compelling" biotech investment opportunity for several reasons, including a senior leadership team with deep biopharma roots, the unique spinout origin story from AstraZeneca (AZN), and large total addressable markets across various autoimmune diseases, Fernandez tells investors in a research note. With five biologic assets including inebilizumab already filed with the FDA, Viela "is well on its way to being a fully integrated biotechnology company focused on autoimmune disease," contends the analyst.
09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Competitor PARP data an incremental negative for Clovis, says JPMorgan
JPMorgan analyst Cory Kasimov said he views the Phase 3 data presented by AstraZeneca (AZN) and Merck (MRK) on their PARP inhibitor Lynparza in previously treated prostate cancer as incrementally negative to Clovis (CLVS), which has "a lot riding on the prostate indication" since its Rubraca is "neck-and-neck with the competition to be first to market." While there wasn't anything bad reported at the ESMO meeting from Clovis' own prostate update, AstraZeneca "looks primed to come to market with a much more robust data set" and Clovis may "be playing catch-up" in another cancer indication, said Kasimov, who keeps a Neutral rating on Clovis shares.
BMY Bristol-Myers
$58.00

0.41 (0.71%)

08/27/19
RBCM
08/27/19
NO CHANGE
Target $206
RBCM
Sector Perform
Amgen price target raised to $206 from $192 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Amgen to $206, saying that despite the "sticker shock" of its $13.4B deal for the Otezla franchise, the transaction is expected to be immediately accretive to earnings and fitting well with its existing inflammation and immunology portfolio. The analyst believes that Amgen should be able to grow revenue "majorly" over the next 3 years as it leverages Otezla potential with its legal victory on Enbrel, stating that there is a case for its multiple to re-rate higher. MacKay keeps his Sector Perform rating on Amgen shares as he awaits for its emerging pipeline to also "fill the shoes" of its maturing assets.
10/16/19
BOFA
10/16/19
INITIATION
Target $60
BOFA
Buy
Bristol-Myers reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Bristol-Myers with a Buy rating and $60 price target. The analyst said overall he is bullish on the combined company, citing "several higher-impact catalysts on the horizon" that could result in a re-rating the stock.
08/19/19
MZHO
08/19/19
DOWNGRADE
MZHO
Neutral
Amgen, Celgene downgraded to Neutral on valuation at Mizuho
As previously reported, Mizuho analyst Salim Syed downgraded Amgen (AMGN) and Celgene (CELG), each to Neutral from Buy, "solely" on the stock's current trading prices nearing what the analyst views as appropriate valuations. Amgen has run up over the last week by about 10% following a "very clean Enbrel litigation win," but the stock price now gives full credit for its Enbrel IP, said Syed, who raised his price target on Amgen shares to $212 from $208. He also cut his price target on Celgene shares to $100 from $103, based on a calculation of one Bristol-Myers (BMY) share being worth $47, plus $50 cash per share and $3 for a risk-adjusted CVR valuation.
11/07/19
PIPR
11/07/19
NO CHANGE
Target $35
PIPR
Overweight
Nektar price target lowered to $35 from $50 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target for Nektar Therapeutics (NKTR) to $35 from $50 citing trial timeline delays following the company's Q3 results. The analyst, however, keeps an Overweight rating on the shares. Three of six planned registrational trials are ongoing with partner Bristol-Myers (BMY), and management on the call updated the timelines for topline readouts in these trials, which are delayed approximately a year, says Van Buren. He looks forward to the melanoma/PIVOT-02 cohort update at SITC this weekend and is "encouraged to see more of the pipeline advance into clinical development," saying Nektar continues to diversify beyond bempeg.
GILD Gilead
$65.34

1.36 (2.13%)

10/25/19
MAXM
10/25/19
DOWNGRADE
Target $66
MAXM
Hold
Gilead downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Gilead to Hold from Buy with a price target of $66, down from $84. The analyst notes that the company's Q3 results were "in line" with expectations, but he remains concerned about its near-term growth prospects. McCarthy points to a lack of potential catalysts as Gilead's HCV revenue continues to erode and its HIV franchise is not enough to generate a "significant" revenue growth.
10/25/19
MAXM
10/25/19
DOWNGRADE
MAXM
Hold
Gilead downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Gilead to Hold from Buy.
10/25/19
OPCO
10/25/19
NO CHANGE
Target $80
OPCO
Outperform
Gilead price target lowered to $80 from $85 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Gilead to $80 from $85 and maintained an Outperform rating following the company's Q3 earnings report and investor update. While the quarter was in line with consensus estimates, it missed his expectations by 2% on the top line and bottom line due to one-offs for the HIV/HCV franchise, Singh tells investors in a research note. As new management slot in, Singh says he expects further updates on commercial execution and the pipeline, but HIV continues to be strong, HCV is stabilizing, Yescarta still has "surprising" quarterly variations while the filgotinib filing timelines have firmed up.
10/29/19
RBCM
10/29/19
NO CHANGE
RBCM
Top Pick
Gilead design of Phase 2 study of GS-6207 'intriguing,' says RBC Capital
RBC Capital analyst Brian Abrahams noted that details on Gilead's Phase 2 study for its capsid inhibitor, GS-6207, were posted today on clinicaltrials.gov. He calls the design of the study "intriguing," telling investors that the dose and duration suggest that the drug's profile "may look even better than previously disclosed." The analyst, who sees potential for a transformation of the HIV treatment paradigm away from orals, maintains Gilead shares as a Top Pick.
NWBO Northwest Biotherapeutics
$0.00

(0.00%)

NVS Novartis
$88.40

1.34 (1.54%)

10/08/19
PIPR
10/08/19
NO CHANGE
Target $435
PIPR
Overweight
Piper positive on Regeneron after 'significant let-down' Novartis label
Piper Jaffray analyst Christopher Raymond is "incrementally positive" on Regeneron Pharmaceuticals (REGN) after the FDA approved Novartis' (NVS) Beovu for the treatment of wet age-related macular degeneration. While the approval was anticipated and physician anticipation of the drug has been high, doctors are likely to view the drug's label "as a significant let-down," Raymond tells investors in a research note. The analyst says that with inflammation and immunogenicity rates meaningfully higher than Regeneron's Eylea, and the lack of flexibility to dose more frequently, he sees little reason for doctors to switch. And while some investors may point to price as another meaningful lever, off-label Avastin makes for an "insurmountable bar for the price-sensitive segment," says Raymond. He keeps an Overweight rating on Regeneron shares with a $435 price target. The label "renders Beovu as little more than an also-ran," contends the analyst. As such, Raymond thinks Eylea's dominance in remains intact.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
NEO NeoGenomics
$22.69

0.68 (3.09%)

01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
03/12/19
FANA
03/12/19
NO CHANGE
Target $23
FANA
Strong Buy
NeoGenomics target raised to $23 after company visit at First Analysis
First Analysis analyst Joseph Munda raised his price target for NeoGenomics to $23 from $22 and reiterates a Strong Buy rating on the shares after visiting the company's headquarters. The analyst says a "deep dive" with management on the integration of Genoptix and the pharma services business "raised his conviction level" for the shares. NeoGenomics offers a "one-stop oncology testing shop" that is well positioned to scale its pharma services business and continue to take clinical testing market share, Munda tells investors in a research note.
03/29/19
NEED
03/29/19
NO CHANGE
Target $22
NEED
Buy
NeoGenomics price target raised to $22 from $19 at Needham
Needham analyst Stephen Unger raised his price target on NeoGenomics to $22 and kept his Buy rating after meeting with its CEO Doug VanOort. The analyst says the discussions left him "incrementally bullish" about the company's prospects driven by the doubling of its sales force to 70 representatives that could potentially increase its test volumes. Unger adds that the company's integration of Genoptix is proceeding as planned with no negative surprises, and the "development of a testing panel using next-generation sequencing remains on track for FDA submission before the end of 2019."
04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
MYGN Myriad Genetics
$23.64

0.12 (0.51%)

11/05/19
LEER
11/05/19
NO CHANGE
Target $28
LEER
Market Perform
Myriad Genetics price target lowered to $28 from $37 at SVB Leerink
SVB Leerink analyst Puneet Souda lowered his price target for Myriad Genetics to $28 from $37 and maintained a Market Perform rating, given that its core hereditary cancer franchise continues to see competitive and pricing pressures while its broader testing franchise including GeneSight is unable to shore up the decline. Myriad negatively surprised in yet another quarter, Souda tells investors in a research note, adding that he believes the stock will likely trade down as expectations are reset after what seems to be a string of quarters with negative surprises including impact from Lab Benefit Managers, FDA inquiry, GeneSight ADHD discontinuation and coding changes in its core hereditary business.
09/26/19
BOFA
09/26/19
UPGRADE
BOFA
Buy
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Bruker (BRKR), PerkinElmer (PKI), and Personalis (PSNL) to Buy from Neutral as part of his broader research note into Life Sciences & Diagnostic Tools. The analyst notes that the recent market volatility has sent many of the names in the sector "sharply lower", making their valuations more attractive. de Bruin is also positive on Bruker's new product portfolio and margin expansion opportunity. As part of the research note, the analyst cuts Myriad Genetics (MYGN) to Underperform from Neutral and lowers his price target on the shares to $28 from $30 after a bounce in its stock price and given his concern with its mixed execution.
11/05/19
PIPR
11/05/19
NO CHANGE
Target $22
PIPR
Neutral
Myriad Genetics price target lowered to $22 from $40 at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his price target for Myriad Genetics to $22 from $40 after the company reported a Q1 revenue decline of 7.9% to $186.3M, or well below its guidance of $200M-202M. Even adjusting for an updated accrual revenue would have been below guidance, Quirk tells investors in a research note. He maintains a Neutral rating on Myriad Genetics.
11/05/19
LEHM
11/05/19
NO CHANGE
Target $18
LEHM
Underweight
Myriad Genetics price target lowered to $18 from $22 at Barclays
Barclays analyst Jack Meehan lowered his price target for Myriad Genetics to $18 from $22 saying the company's Q3 results were "very weak," as new pricing pressure in the core hereditary cancer testing franchise brings coding risks "back to the forefront of the thesis." The analyst expects further pricing risks will represent an overhang for the stock. He keeps an Underweight rating on Myriad Genetics.
MRK Merck
$83.59

0.68 (0.82%)

10/30/19
MZHO
10/30/19
NO CHANGE
Target $100
MZHO
Buy
Merck price target raised to $100 from $97 at Mizuho
Mizuho analyst Mara Goldstein raised her price target for Merck to $100 from $97 saying the company delivered a "strong" Q3 earnings beat and raised fiscal 2019 sales and EPS guidance. The analyst continues to see opportunity for Keytruda to drive a profit transformation over the next several years and reiterates a Buy rating on the shares.
10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill
11/08/19
LEER
11/08/19
NO CHANGE
LEER
Outperform
Merck data a 'much needed positive' for Aduro Biotech, says SVB Leerink
SVB Leerink analyst Daina Graybosch noted that Merck (MRK) presented data in a late-breaking oral session at the SITC meeting on the dose escalation and confirmation phases of its trial of MK-5890, which is licensed from Aduro Biotech (ADRO). The "surprisingly positive" signal in dose escalation, while very early, should not have much stock impact for Merck, but for Aduro "this is some much needed positive news," according to Graybosch. She has an Outperform rating on Aduro shares.
10/18/19
MZHO
10/18/19
NO CHANGE
Target $97
MZHO
Buy
Merck's Keytruda pulling farther ahead of competition, says Mizuho
Mizuho analyst Mara Goldstein reiterated her Buy rating and $97 price target on Merck shares after the announcement of positive EU CHMP opinions for Keytruda monotherapy and in combination with chemotherapy for first-line head and neck squamous cell carcinoma, or HNSCC. She sees Keytruda pulling farther ahead of its competition as the leading checkpoint inhibitor as it continues to penetrate additional tumor types and global markets, Goldstein tells investors.
FPRX Five Prime
$3.90

0.01 (0.26%)

06/03/19
06/03/19
DOWNGRADE
Target $10

Market Perform
Five Prime downgraded to Market Perform following ASCO data at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough downgraded Five Prime Therapeutics to Market Perform from Outperform following review of data at ASCO for B7:H4 antibody FPA-150 in B7:H4+ patients with solid tumors including ovarian cancer. The analyst says overall response rate of 1/18 in B7:H4+ tumors was "underwhelming," with lack of clarity on dose response. Birchenough also lowered his price target on the shares to $10 from $35.
06/03/19
WELS
06/03/19
DOWNGRADE
Target $10
WELS
Market Perform
Five Prime downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo Securities analyst Jim Birchenough downgraded Five Prime Therapeutics to Market Perform from Outperform and lowered his price target for the shares to $10 from $35.
09/30/19
GUGG
09/30/19
DOWNGRADE
GUGG
Neutral
Five Prime downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Five Prime Therapeutics to Neutral from Buy.
10/01/19
GUGG
10/01/19
DOWNGRADE
GUGG
Neutral
Five Prime cut to Neutral after ESMO readout, management exits at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt downgraded Five Prime Therapeutics to Neutral from Buy and removed his previous $15 price target on the stock. The company's Phase Ib/II data on FPA150 reported at the ESMO congress demonstrated "modest" efficacy in B7-H4-high patients at the expansion dose, said Schmidt. He also thinks that the recent departure of CEO Aron Knickerbocker following CSO Bryan Irving's exit does not inspire confidence in the company's platform and pipeline. Five Prime also has low visibility on its out-licensed programs, according to Schmidt.

TODAY'S FREE FLY STORIES

20:20
11/21/19
11/21
20:20
11/21/19
20:20
General news
Treasury Market Summary »

Treasury Market Summary:…

LYV

Live Nation

$66.17

-1.55 (-2.29%)

20:08
11/21/19
11/21
20:08
11/21/19
20:08
Periodicals
Live Nation 'looking forward' to taking part in Congress review of ticket market 

Report from Bloomberg.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRH

DiamondRock

$9.86

-0.085 (-0.86%)

19:53
11/21/19
11/21
19:53
11/21/19
19:53
Upgrade
DiamondRock rating change at Wells Fargo »

DiamondRock upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OOMA

Ooma

$11.18

-0.01 (-0.09%)

, IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

19:18
11/21/19
11/21
19:18
11/21/19
19:18
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ooma…

OOMA

Ooma

$11.18

-0.01 (-0.09%)

IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

JWN

Nordstrom

$34.29

0.35 (1.03%)

SCVL

Shoe Carnival

$37.18

1.36 (3.80%)

SPLK

Splunk

$126.80

-0.04 (-0.03%)

GPS

Gap

$16.22

-0.05 (-0.31%)

ROST

Ross Stores

$111.81

1.39 (1.26%)

PSTG

Pure Storage

$19.84

-0.22 (-1.10%)

WSM

Williams-Sonoma

$68.76

0.195 (0.28%)

PNNT

PennantPark

$5.95

0.01 (0.17%)

ENTA

Enanta

$63.27

1.55 (2.51%)

INTU

Intuit

$270.01

-3.38 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 22

    Nov

  • 22

    Nov

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 10

    Mar

  • 11

    Mar

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:08
11/21/19
11/21
19:08
11/21/19
19:08
Earnings
AES backs FY19 adjusted EPS view $1.30-$1.38, consensus $1.33 »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

WM

Waste Management

$111.23

-1.305 (-1.16%)

, RSG

Republic Services

$86.78

-0.91 (-1.04%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Initiation
Waste Management, Republic Services, Waste Connections, Clean Harbors, Stericycle, Casella Waste, Covanta initiated  »

Jefferies initiates…

WM

Waste Management

$111.23

-1.305 (-1.16%)

RSG

Republic Services

$86.78

-0.91 (-1.04%)

WCN

Waste Connections

$89.54

-0.28 (-0.31%)

CLH

Clean Harbors

$84.70

-0.75 (-0.88%)

SRCL

Stericycle

$62.49

0.76 (1.23%)

CWST

Casella Waste

$43.70

-0.39 (-0.88%)

CVA

Covanta

$14.43

-0.14 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Hot Stocks
AES Corp. says PUCO has modified DP&L rates »

The AES Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

, BTC

Bitcoin

$0.00

(0.00%)

19:02
11/21/19
11/21
19:02
11/21/19
19:02
Hot Stocks
ICE announces launch of Bakkt Bitcoin Cash Settled Monthly Futures contract »

Intercontinental Exchange…

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAN

ManpowerGroup

$92.05

-0.355 (-0.38%)

18:51
11/21/19
11/21
18:51
11/21/19
18:51
Initiation
ManpowerGroup initiated at Jefferies »

ManpowerGroup initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHI

Robert Half

$58.01

-0.38 (-0.65%)

18:48
11/21/19
11/21
18:48
11/21/19
18:48
Initiation
Robert Half initiated at Jefferies »

Robert Half initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTZ

Hertz

$15.37

0.265 (1.76%)

18:46
11/21/19
11/21
18:46
11/21/19
18:46
Initiation
Hertz initiated at Jefferies »

Hertz initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$28.71

0.16 (0.56%)

18:44
11/21/19
11/21
18:44
11/21/19
18:44
Initiation
Avis Budget initiated at Jefferies »

Avis Budget initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$39.52

-1.45 (-3.54%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Hot Stocks
AMD CEO: The key for us is product generation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CTAS

Cintas

$253.61

-5.78 (-2.23%)

, BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Initiation
Cintas, Bright Horizons, Aramark, H&R Block, BrightView, Rollins, ServiceMaster initiated at Jefferies »

Jefferies initiates…

CTAS

Cintas

$253.61

-5.78 (-2.23%)

BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

ARMK

Aramark

$42.42

-1.37 (-3.13%)

HRB

H&R Block

$24.34

-0.15 (-0.61%)

BV

BrightView

$16.79

-2.525 (-13.08%)

ROL

Rollins

$35.77

-0.8 (-2.19%)

SERV

ServiceMaster

$36.16

-0.42 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

PINE

Alpine Income Properties

$0.00

(0.00%)

18:34
11/21/19
11/21
18:34
11/21/19
18:34
Syndicate
Alpine Income Properties 7.5M share IPO priced at $19.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

OTTW

Ottawa Bancorp

$13.39

-0.39 (-2.83%)

18:28
11/21/19
11/21
18:28
11/21/19
18:28
Hot Stocks
Ottawa Bancorp approves stock buyback of 317,307 shares »

Ottawa Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$149.46

-0.14 (-0.09%)

18:27
11/21/19
11/21
18:27
11/21/19
18:27
Periodicals
Microsoft says granted U.S. license to do business with Huawei, Bloomberg says »

Microsoft said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

SITC

Site Centers

$14.28

-0.275 (-1.89%)

18:24
11/21/19
11/21
18:24
11/21/19
18:24
Upgrade
Site Centers rating change at Stifel »

Site Centers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Airlines

$90.96

-0.72 (-0.79%)

, BA

Boeing

$366.47

-4.275 (-1.15%)

18:23
11/21/19
11/21
18:23
11/21/19
18:23
Hot Stocks
United Airlines CEO: We don't think we are near a recession »

In an interview on…

UAL

United Airlines

$90.96

-0.72 (-0.79%)

BA

Boeing

$366.47

-4.275 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FAST

Fastenal

$35.15

-0.1 (-0.28%)

, GWW

Grainger

$312.66

0.305 (0.10%)

18:20
11/21/19
11/21
18:20
11/21/19
18:20
Initiation
Fastenal, Grainger, HD Supply, MSC Industrial, Wesco initiated at Jefferies »

Jefferies initiates…

FAST

Fastenal

$35.15

-0.1 (-0.28%)

GWW

Grainger

$312.66

0.305 (0.10%)

HDS

HD Supply

$39.10

-0.21 (-0.53%)

MSM

MSC Industrial

$73.66

-0.125 (-0.17%)

WCC

Wesco

$53.09

-0.02 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 30

    Jan

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

, INFO

IHS Markit

$71.62

-0.38 (-0.53%)

18:06
11/21/19
11/21
18:06
11/21/19
18:06
Initiation
S&P Global, IHS Markit, Verisk Analytics, Gartner, FactSet, Equifax, TransUnion, CoStar Group initiated at Jefferies »

Jefferies initiates…

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

INFO

IHS Markit

$71.62

-0.38 (-0.53%)

VRSK

Verisk Analytics

$144.45

0.12 (0.08%)

IT

Gartner

$158.00

0.06 (0.04%)

FDS

FactSet

$258.20

-3.65 (-1.39%)

EFX

Equifax

$137.97

-1.15 (-0.83%)

TRU

TransUnion

$84.90

-1.34 (-1.55%)

CSGP

CoStar Group

$587.66

-7.45 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 19

    Dec

  • 19

    Dec

  • 07

    Jan

GPS

Gap

$16.22

-0.05 (-0.31%)

17:59
11/21/19
11/21
17:59
11/21/19
17:59
Periodicals
Gap to pull Old Navy brand from China in early 2020, Reuters reports »

Gap said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

LB

L Brands

$17.18

1.78 (11.56%)

17:50
11/21/19
11/21
17:50
11/21/19
17:50
Hot Stocks
L Brands cancels Victoria's Secret Fashion Show for 'more current platforms' »

The CFO of L Brands,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

  • 27

    Feb

WCC

Wesco

$53.09

-0.02 (-0.04%)

17:47
11/21/19
11/21
17:47
11/21/19
17:47
Initiation
Wesco initiated at Jefferies »

Wesco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAN

ManpowerGroup

$92.05

-0.355 (-0.38%)

17:47
11/21/19
11/21
17:47
11/21/19
17:47
Initiation
ManpowerGroup initiated at Jefferies »

ManpowerGroup initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.